Advanced digital technologies to enhance drug discovery
year has also seen deeper implementation and alignment towards decentralized trials . The industry is also witnessing an increasing number of registered clinical trials globally , with a growing complexity of trials and a large number of drugs in the R & D pipeline . Initiatives like patient-guided outcome measures and advisory boards ensure that trials are designed with the patient in mind . Efforts to improve diversity and inclusion are evident , aiming to make the benefits of new therapies accessible to diverse populations .
In 2023 , Parexel garnered various awards and recognitions that highlighted its commitment to excellence in the clinical trials industry and customer satisfaction .
Some of the awards include Best Contract Research Organization at 19th Annual Scrip Awards , 2023 Society for Clinical Research Sites ( SCRS ) Eagle Award ( CRO category ) and ‘ Top CRO to Work With ’ in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight Time .
Parexel made strategic appointments to strengthen its leadership team , with the appointment of Gwyn Bebb , Ph . D ., to lead Oncology Clinical Development and the addition of Michael Bruun and John Groetelaars to its Board of Directors . Scott Smith , M . D ., Ph . D ., was also appointed as the new Head of Hematology , further enhancing
Parexel ' s expertise in critical areas .
In terms of collaborations , Parexel entered into a strategic alliance with Partex , leveraging Artificial Intelligence and big data to accelerate drug discovery and development . Parexel also introduced the ‘ Expert Series – New Medicines , Novel Insights ’, showcasing its dedication to providing valuable insights and expertise in the field .
Advanced digital technologies to enhance drug discovery
For Parexel India , the future prospects for clinical trials in 2024 and beyond are promising , with advancements in technology and methodologies expected to improve trial efficiency , diversity , and patient centricity . We will continue to work towards making India the global hub for clinical trials .
We will continue to invest further in using technology and patient insights to support our clinical trial designs due to the increasing complexity and greater data volume and diversity . The use digital technologies such as Artificial Intelligence , Machine Learning and Deep Learning are expected to enhance drug discoveries , trial efficiency , diversity , and patient centricity in 2024 . Furthermore , the use of artificial intelligence , machine learning , and deep neural networks is anticipated to improve drug discovery and trial methodologies .
BIOVOICENEWS . COM 19